OR WAIT null SECS
Aims to grow its digital clinical trial offerings internationally
Medable Inc., a cloud platform company for patient-centered drug development who last month partnered with Aural Analytics on the National Institute of Health’s Beau Biden Cancer Moonshot program, announced the first stage of its European expansion plans with a new EMEA (Europe, the Middle East and Africa) headquarters in Dublin. The regional HQ will function as the center of expanded sales, customer success and software development in Europe, allowing Medable to continue adoption of digital clinical trials at a global level.
According to the company, the European expansion is aimed at facilitating more engagement with hundreds of pharma, biotech and medical device companies across the UK, Germany, Switzerland, Spain and Benelux. Medable’s European operations will also assist the company with clinical trial deployments in the region, specifically by providing remote and site-based access for patients anywhere.
Medable. who has employees that are currently based in the UK, Germany, and Denmark among other locations in Europe, plans to create as many as 50 positions in Dublin over the next three years.
“Medable has played a valuable role in making clinical trials more accessible and inclusive for diverse patient populations, and we’re excited to deepen our roots in Europe,” says Dr. Michelle Longmire, CEO and co-founder of Medable. “Our vision for the future of clinical research is based on consumer-scale technology that serves billions of patients through mobile applications and connected devices. We look forward to working with more partners, customers and patients across Europe as we expand our ecosystem and investments.”